Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride

Lambert, Martin; Naber, Dieter; Eich, F.X.; Schacht, Melanie; Lindén, Michael; Schimmelmann, Benno G.

doi:10.1111/j.1600-0447.2006.00862.x

Cited by 60 publications

(53 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Treatment with blonanserin increased the mean SWNS-J total scores by 19.1 points between baseline and end-point. A significant improvement over baseline was also observed in most of the SWN subscales and the extent of the increase in mean scores was similar in all the five domains examined.…”

Section: Effect Of Blonanserin On Subjective Well-being and Qolmentioning

confidence: 93%

“…The SWNS-J total score at baseline was under 60 points, which indicated a 'markedly' to 'very much' impaired subjective well-being rating according to the SWN impairment criterion. 23 Treatment with blonanserin increased the mean SWNS-J total scores by 19.1 points between baseline and end-point. A significant improvement over baseline was also observed in most of the SWN subscales and the extent of the increase in mean scores was similar in all the five domains examined.…”

Section: Effect Of Blonanserin On Subjective Well-being and Qolmentioning

confidence: 93%

See 1 more Smart Citation

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Ninomiya

Miyamoto

Tenjin

et al. 2014

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aims:The purpose of this study was to evaluate the long-term effectiveness and safety of blonanserin, a second-generation antipsychotic drug developed in Japan, in patients with first-episode schizophrenia.Methods: Twenty-three antipsychotic-naïve patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of blonanserin (2-24 mg/day). Clinical evaluations were conducted at baseline and 2, 6, and 12 months after the start of treatment. The main outcome measures were changes in subjective well-being and subjective quality of life, as assessed by the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version and the Schizophrenia Quality of Life Scale-Japanese version, respectively. Secondary outcome measures included the Positive and Negative Syndrome Scale, the Brief Assessment of Cognition in SchizophreniaJapanese version, laboratory tests, bodyweight, and extrapyramidal symptoms.Results: Fourteen patients (60.9%) remained on the study at 1 year. In the intention-to-treat analysis, significant improvements were observed in several subscales on the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version, the Schizophrenia Quality of Life Scale-Japanese version, and the Brief Assessment of Cognition in Schizophrenia-Japanese version, and in all factor scores on the Positive and Negative Syndrome Scale. Improvement in depressive symptoms with blonanserin treatment was positively correlated with improvements in subjective well-being and subjective quality of life, as well as verbal memory. No significant changes were noted for any safety measure during the 1-year study period. Conclusions:Blonanserin was well tolerated and effective for the treatment of first-episode schizophrenia in terms of subjective wellness, cognition, and a wide range of pathological symptoms. Further largescale studies are warranted to confirm our findings.Key words: blonanserin, cognition, first-episode schizophrenia, second-generation antipsychotics, subjective well-being. SCHIZOPHRENIA IS A chronic and debilitating disorder characterized by positive, negative, cognitive, and affective symptoms. Second-generation antipsychotics (SGA), excluding clozapine, are currently recommended in many guidelines as firstline agents for acute and maintenance therapy for schizophrenia. In four randomized, short-term, double-blind trials in patients with chronic schizophrenia, 3-6 blonanserin was shown to be as effective as haloperidol and risperidone in improving positive symptoms, and superior to haloperidol in improving negative symptoms. The overall safety profile of blonanserin Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Email: y2ninomiya@marianna-u.ac.jp Received 25 December 2013; revised 19 April 2014; accepted 11 May 2014. R e t r a c t e dhas been similar to that of haloperidol and risperidone, 3,4,6,7 but blonanserin has been associated with a lower incidence of extrapyramidal symptoms (EPS) than haloperidol. 3,8...

show abstract

Section: Effect Of Blonanserin On Subjective Well-being and Qolmentioning

confidence: 93%

Section: Effect Of Blonanserin On Subjective Well-being and Qolmentioning

confidence: 93%

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Ninomiya

Miyamoto

Tenjin

et al. 2014

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…A large study of subjective well-being105 reported that amisulpride treatment was effective in improving patients’ well-being, but much of the response was attributable to the resolution of poorly controlled positive symptoms.…”

Section: Amisulpride and Adaptive Functionmentioning

confidence: 99%

Update on the management of symptoms in schizophrenia: focus on amisulpride

Mortimer¹

2009

NDT

View full text Add to dashboard Cite

Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.

show abstract

“…Baseline and early changes in QOL showed a high predictive validity for later symptomatic remission as well (Boden et al 2009 ;Lambert et al 2007 ). Boden and (2) The two negative symptoms not included in the BPRS (i.e., "social withdrawal" and "lack of spontaneity") need to be additionally assessed with PANSS or SANS when BPRS is used coworker found an early improvement of subjective well-being in schizophrenia signifi cantly associated with enduring symptomatic remission (de Haan et al 2008 ).…”

Section: Symptomatic Remission and Qolmentioning

confidence: 93%

“…The measurement of QOL has been approved by the Food and Drug Administration as outcome parameter for the assessment of novel antipsychotic treatment Lambert et al 2006 ;(FDA) USFaDA 2006 ;Hofer et al 2007 ). Various studies reported a signifi cant QOL improvement under antipsychotic treatment, which is signifi cantly associated with early treatment response, improvement in symptoms, subjective effectiveness, medication compliance, a low level of neuroleptic-induced dysphoria, and lower rates of antipsychotic side effects such as sedation, obesity, and sexual side effects (Lambert et al 2007 ;Schimmelmann et al 2005 ;Putzhammer et al 2005 ;DeHaan et al 2002 ;Karow et al 2007 ;Sugawara et al 2013 ). Patients with a fi rst episode of psychosis reported lower levels of QOL at start of antipsychotic treatment and better QOL improvement during treatment compared with patients with multiple episodes (Yeh et al 2013 ).…”

Section: Antipsychotic Treatment and Qolmentioning

confidence: 99%

Beyond Assessment of Quality of Life in Schizophrenia

Awad¹,

Voruganti²

2016

View full text Add to dashboard Cite

Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride

Abstract: Patients with a risk of SW non-remission need to be identified early with subsequent treatment adaptation according to recommendations for incomplete remission and treatment resistance in schizophrenia.

Cited by 60 publications

References 25 publications

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Update on the management of symptoms in schizophrenia: focus on amisulpride

Beyond Assessment of Quality of Life in Schizophrenia

Contact Info

Product

Resources

About